In April 2016 Manchester eScholar was replaced by the University of Manchester’s new Research Information Management System, Pure. All scholarly work records and full-texts stored in Manchester eScholar were migrated to the new system prior to this transition. From August 2016 the University’s research outputs will be available to view and download via the new Research Portal. Until then the old eScholar content WILL BE TEMPORARILY available to search and browse via this archive.

Choice of Treatment Affects Plasma-Levels of Insulin-Like Growth Factor-Binding Protein-1 in Noninsulin-Dependent Diabetes-Mellitus

Gibson, J M; Westwood, M; Crosby, S R; Gordon, C; Holly, J M P; Fraser, W; Anderson, C; White, A; Young, R J

Journal of Clinical Endocrinology & Metabolism. 1995;80(4):1369-1375.

Access to files

Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:

Full-text held externally

Abstract

Insulin-like growth factor (IGF)-binding protein-1 (IGFBP-1) modulates the metabolic and mitogenic effects of IGFs. Although IGFBP-1 levels are abnormally high in insulin-dependent diabetes (IDDM), relatively little is known in NIDDM; conflicting data have suggested both high and low levels. We investigated whether treatment modifies IGFBP-1 levels in two groups of NIDDM patients. Study 1 examined fasting concentrations in groups of patients with NIDDM, comparable except for treatment type (sulfonylurea, n = 23; once daily insulin, n = 15; sulfonylurea plus once daily insulin, n = 14; multiple insulin injections, n = 9) and 25 nondiabetic subjects. In sulfonylurea-treated patients there were markedly reduced plasma IGFBP-1 concentrations (median, interquartile range in parentheses): control, 61.0 (36-96) mu g/L; sulfonylureas alone, 31.5 (21-61) mu g/L (P < 0.01); and sulfonylureas plus insulin, 31.5 (9-53) mu g/L (P < 0.01). Once daily insulin was associated with values similar to those in the control group [62.0 (27-103) mu g/L; P = NS], whereas IGFBP-1 levels were higher with multiple insulin injection therapy [156.0 (71-184) mu g/L; P < 0.05]. Proinsulin levels were higher in sulfonylurea-treated patients, but there was no significant correlation between IGFBP-1 and proinsulin within any individual group. Study 2 examined the effects of treatment on the dynamics of IGFBP-1 levels between 0800-1900 h. In control subjects (n = 8), levels fell from 0800 h (mean +/- SEM, 22.4 +/- 5.2 mu g/L) to 1000 h (14 +/- 5.2 mu g/L), followed by a rise, more rapid after food, to a peak at 1240 h (20.6 +/- 3.7 mu g/L). Levels then declined until 1500 h (10.7 +/- 2.9 mu g/L), with a further postprandial peak at 1840 h (23.1 +/- 3.2 mu g/L). Sulfonylurea therapy (n = 6) resulted in a complete loss of this pattern, with a marked fall in IGFBP-1 from 0800 h (22 +/- 2.7 mu g/L) to less than 7 mu g/L for the remainder of the study (area under the curve, 1150-1400 h, P < 0.001 vs. control). By contrast, in metformin-treated patients (n = 7), neither IGFBP-1 levels nor postprandial peaks were significantly different from those in the control group. Our findings suggest that in patients with NIDDM, the regulation of IGFBP-1 is markedly influenced by the choice of treatment.

Bibliographic metadata

Type of resource:
Content type:
Published date:
ISSN:
Volume:
80
Issue:
4
Start page:
1369
End page:
1375
Total:
7
Pagination:
1369-1375
ISI Accession Number:
ISI:A1995QR24300059
Related website(s):
  • Related website <Go to ISI>://A1995QR24300059
Access state:
Active

Institutional metadata

University researcher(s):

Record metadata

Manchester eScholar ID:
uk-ac-man-scw:151205
Created by:
Gibson, Martin
Created:
15th January, 2012, 15:04:02
Last modified by:
Gibson, Martin
Last modified:
1st February, 2013, 19:45:37

Can we help?

The library chat service will be available from 11am-3pm Monday to Friday (excluding Bank Holidays). You can also email your enquiry to us.